SCHEDULE: Research Alliance III Announces Business Combination with OHB Pediatrics

Research Alliance Corporation III has entered into a Business Combination Agreement to acquire OHB Pediatrics Ltd., with an expected closing in the second half of 2026.

Summary

• Research Alliance Corporation III (the "Issuer") has entered into a Business Combination Agreement with OHB Pediatrics Ltd. (the "Company") and its shareholders.
• The agreement outlines the acquisition of 100% of the outstanding shares of the Company by the Issuer in exchange for newly issued shares of Research Alliance Corporation III common stock.
• The transaction is expected to close in the second half of 2026, subject to shareholder approval and other customary closing conditions.
• Prior to closing, the Issuer will undergo a domestication from the Cayman Islands to Delaware and convert its Class B ordinary shares to Class A ordinary shares.
• The acquisition's consideration is based on an Adjusted Equity Value, calculated as a base equity value of $160,000,000 plus the Company SAFE Amount.
• The Company has secured interim financing of $45,000,000 through simple agreements for future equity (SAFEs) from RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund IV, L.P.
• A backstop agreement is in place with RA Capital Healthcare Fund, L.P. to subscribe for up to 7,500,000 shares of common stock at $10.00 per share to cover potential shareholder redemptions.
• An Investor Rights Agreement will be entered into at closing, requiring the Issuer to file a resale registration statement within 30 days.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it confirms a definitive agreement for a business combination with clear terms and a defined timeline, though significant closing conditions and potential redemptions introduce uncertainty.

Positives

• Definitive agreement reached for a business combination with OHB Pediatrics Ltd.
• Expected closing in the second half of 2026, indicating a defined timeline.
• Interim financing of $45,000,000 secured for OHB Pediatrics Ltd.
• Backstop agreement in place to support potential shareholder redemptions, ensuring capital stability.
• Planned domestication to Delaware and listing on Nasdaq Capital Market, potentially enhancing market access and investor confidence.
• Management team, including Matthew Hammond as CEO, will continue to lead the combined entity.
• Agreement for an Investor Rights Agreement to facilitate resale of securities post-closing.

Negatives

• The transaction is subject to shareholder approval, which is not guaranteed.
• Closing is contingent on numerous conditions, including antitrust approvals and effectiveness of registration statements.
• Potential for significant shareholder redemptions, which could impact the capital structure.
• The valuation is contingent on the 'Adjusted Equity Value' which includes the 'Company SAFE Amount', potentially increasing the effective purchase price.
• Lock-up agreements will restrict the sale of shares for six months post-closing for certain shareholders.

Risks

• Failure to obtain requisite shareholder approvals for the business combination.
• Inability to satisfy other customary closing conditions, such as regulatory approvals (e.g., HSR Act) or listing on Nasdaq.
• Significant shareholder redemptions could deplete the trust account and impact the capital available for the combined entity.
• Potential for material adverse effects on either the Issuer or the Company prior to closing.
• The business combination is subject to termination under various circumstances, including failure to close within six months.
• The effectiveness of the Registration Statement / Proxy Statement is a condition to closing.

Future Outlook

The transaction is expected to close in the second half of 2026, following shareholder approval and fulfillment of customary closing conditions. Post-closing, the combined entity will be domiciled in Delaware and aims to list on the Nasdaq Capital Market. An Investor Rights Agreement will ensure the filing of a resale registration statement shortly after closing.

Management Comments

• The Reporting Persons have agreed to file this Schedule 13D/A jointly.
• Matthew Hammond is the Manager of RA Holdings III and possesses voting and dispositive control over securities held by RA Holdings III.
• Matthew Hammond is the Chief Executive Officer and Director of the Issuer.
• The Business Combination Agreement and Transactions were unanimously approved by the boards of directors of both the Issuer and the Company.
• RA Holdings III and each Other Class B Shareholder have agreed to vote in favor of the Business Combination Agreement and Transactions.

Industry Context

StockSavvy.ai notes that this filing details a typical Special Purpose Acquisition Company (SPAC) business combination. The structure, including the domestication to Delaware, Nasdaq listing aspirations, and the use of SAFEs and backstop agreements, aligns with common practices in the SPAC market, particularly for companies seeking to go public in the healthcare sector.

Comparison to Industry Standards

• The structure of the business combination, including the exchange ratio calculation based on Adjusted Equity Value and the Base Equity Value of $160,000,000, is a common approach in SPAC mergers.
• The use of SAFEs for interim financing by entities like RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund IV, L.P. is a standard practice to bridge funding gaps before a business combination.
• The backstop agreement mechanism, where RA Capital Healthcare Fund, L.P. commits to purchase shares to cover redemptions at $10.00 per share, is a typical feature designed to provide capital certainty for the target company and the SPAC.
• The planned domestication from the Cayman Islands to Delaware is a frequent move for SPACs to align with U.S. corporate law and investor expectations.
• The commitment to file a resale registration statement post-closing under the Investor Rights Agreement is a standard requirement to facilitate liquidity for investors.

Corporate Governance

Related Party Transactions

• RA Holdings III, managed by Matthew Hammond, holds 1,520,269 shares (275,000 Class A, 1,245,269 Class B).
• Matthew Hammond is the Manager of RA Holdings III and CEO/Director of the Issuer.
• RA Holdings III and Other Class B Shareholders entered into a Sponsor Letter Agreement, agreeing to vote in favor of the transaction and waive certain anti-dilution protections.
• RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund IV, L.P. (related to RA Capital) provided interim financing via Company SAFEs.
• RA Capital Healthcare Fund, L.P. entered into a Backstop Agreement to purchase shares.
• An Investor Rights Agreement will be entered into with RA Holdings III, RA Capital Healthcare Fund, L.P., and RA Capital Nexus Fund IV, L.P. post-closing.

Stakeholder Impact

• Shareholders: Holders of Class A ordinary shares have redemption rights. Holders of Class B shares (RA Holdings III, etc.) are supporting the transaction and subject to lock-up agreements. All shareholders will be subject to the new governance structure and potential dilution from the business combination.
• Management: Matthew Hammond, CEO and Director, will continue to lead the combined entity.
• Creditors: The interim financing via SAFEs impacts the capital structure of OHB Pediatrics Ltd.
• Suppliers/Customers: The business combination aims to grow OHB Pediatrics Ltd., which could impact its relationships with suppliers and customers.

Next Steps

• Obtain requisite approval from Issuer's shareholders.
• Fulfill other customary closing conditions, including antitrust review and Nasdaq listing approval.
• Complete the domestication of the Issuer from the Cayman Islands to Delaware.
• Complete the Share Acquisition of OHB Pediatrics Ltd.
• File a resale registration statement within 30 days of closing.

Key Dates

Recommendation

The filing confirms a definitive agreement for a business combination, which is a significant step. However, the transaction is still subject to numerous closing conditions, including shareholder approval and regulatory hurdles. The potential for substantial redemptions also introduces uncertainty regarding the final capital structure. Therefore, a 'hold' recommendation is appropriate pending further clarity on these factors and the successful completion of the merger.

Keywords

Business Combination, SPAC, Merger, OHB Pediatrics, Research Alliance Corporation III, Healthcare, Delaware Domestication, Nasdaq Listing